US 12,460,255 B2
Compositions and methods to detect adenovirus nucleic acids and metapneumovirus and/or rhinovirus nucleic acids
Mehrdad R. Majlessi, Escondido, CA (US); Ankur Shah, San Diego, CA (US); Amber Hillius, San Diego, CA (US); Pamela Douglass, Kansas City, MO (US); and Daniel Kolk, Ramona, CA (US)
Assigned to GEN-PROBE INCORPORATED, San Diego, CA (US)
Filed by Gen-Probe Incorporated, San Diego, CA (US)
Filed on Dec. 27, 2022, as Appl. No. 18/146,508.
Application 18/146,508 is a continuation of application No. 17/820,256, filed on Aug. 17, 2022.
Application 17/820,256 is a continuation of application No. 17/834,578, filed on Jun. 7, 2022.
Application 17/834,578 is a continuation of application No. 16/497,229, granted, now 11,384,387, issued on Jul. 12, 2022, previously published as PCT/US2018/024141, filed on Mar. 23, 2018.
Claims priority of provisional application 62/476,753, filed on Mar. 25, 2017.
Prior Publication US 2023/0203571 A1, Jun. 29, 2023
Int. Cl. C12Q 1/6844 (2018.01); C12Q 1/70 (2006.01)
CPC C12Q 1/6844 (2013.01) [C12Q 1/701 (2013.01); C12Q 2600/16 (2013.01)] 22 Claims
 
1. A composition comprising a combination of amplification oligomers configured for amplification of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, wherein:
(A) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs: 1, 5, 11, 12, 25, 26, 31 to 34, 35, 38, and 71 to 74, and a second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs: 2, 3, 6 to 9, 13 to 16, 27, 28, 42 to 46, 61, 62, and 138 to 149; and
(B) for the at least one additional target nucleic acid,
(1) (a) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 880 to 915 of SEQ ID NO:159and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 953 to 995 of SEQ ID NO:159; or
(b) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1000 to 1040 of SEQ ID NO:150 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1073 to 1115 of SEQ ID NO:150; and/or
(2) (a) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 263 to 303 of SEQ ID NO:120 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 480 to 533 of SEQ ID NO:120; or
(b) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 231 to 264 of SEQ ID NO:101 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 455 to 506 of SEQ ID NO:101; or
(c) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 106 to 156 of SEQ ID NO:76 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 338 to 397 of SEQ ID NO:76.